Small cell lung cancer entered 2026 with more clinical pipeline activity than any year in the past decade — driven by atezolizumab maintenance maturation data, novel DLL3-targeted bispecific antibodies, and the first lurbinectedin combination readouts from randomized Phase III trials — fundamentally challenging a disease historically defined by rapid resistance and dismal long-term...